Company news

Guardant Health, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer

June 7, 2021

Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer

May 27, 2021

Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

May 20, 2021

Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers

May 18, 2021

Guardant Health Reports First Quarter 2021 Financial Results

May 5, 2021

Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer

May 2, 2021

Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity

April 29, 2021

Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer

April 26, 2021

Guardant Health to Report First Quarter Financial Results on May 6, 2021

April 11, 2021

Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage Cancer

March 31, 2021

Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360® CDx Test

March 29, 2021

Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer

March 23, 2021

Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers

March 1, 2021

Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021

February 23, 2021

Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer

February 15, 2021

Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

February 3, 2021

Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe

January 17, 2021

Guardant Health Names Michael Bell as New Chief Financial Officer

December 10, 2020

Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering

November 15, 2020

Guardant Health Reports Third Quarter 2020 Financial Results

November 4, 2020

Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020

October 15, 2020

Guardant Health Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling Stockholder

October 14, 2020

Guardant Health Announces Pricing of Public Offering of Common Stock by Selling Stockholder

October 6, 2020

Guardant Health Announces Proposed Public Offering of Common Stock by Selling Stockholder

October 5, 2020

Guardant Health Receives FDA Emergency Use Authorization for its Guardant-19 Next Generation Sequencing-Based COVID-19 Test

August 23, 2020

Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers

August 6, 2020

Guardant Health Reports Second Quarter 2020 Financial Results

August 5, 2020

Guardant Health Announces Collaboration with Radius Health to Develop Liquid Biopsy Companion Diagnostic for Elacestrant

July 29, 2020

Guardant Health Announces Webcast of Second Quarter Financial Results on August 6, 2020

July 20, 2020

Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic

July 7, 2020

Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug Development

June 22, 2020

Guardant Health Appoints Vijaya Gadde to its Board of Directors

June 15, 2020

Guardant Health Announces Full Exercise of Option and Closing of Public Offering

June 7, 2020

Guardant Health Announces Pricing of Upsized Public Offering

May 31, 2020

Guardant Health Reports First Quarter 2020 Financial Results

May 6, 2020

Guardant Health Announces Webcast of First Quarter Financial Results on May 7, 2020

April 29, 2020

Guardant Health Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Outlook

February 23, 2020

Guardant Health to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020

February 9, 2020

Guardant Health Appoints High-Tech-Veteran Kumud Kalia Chief Information Officer

January 20, 2020

Guardant Health Announces Collaboration With Amgen to Develop a Global Liquid Biopsy Companion Diagnostic for AMG 510 KRAS G12C Inhibitor

January 12, 2020

Guardant Health Receives Expanded Medicare Coverage for Guardant360 Across the Vast Majority of Solid Tumor Cancers

December 18, 2019

Guardant Health Reports Third Quarter 2019 Financial Results and Raises 2019 Revenue Guidance

November 6, 2019

Guardant Health to Report Third Quarter 2019 Financial Results on November 7, 2019

November 3, 2019

Guardant Health Initiates ECLIPSE Pivotal Study for its LUNAR-2 Blood Test for Colorectal Cancer Screening

October 22, 2019

← Newer news releases

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 49 decks. Every deck is listed under its year.